RT Journal Article
SR Electronic
T1 A foundation model for clinician-centered drug repurposing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.19.23287458
DO 10.1101/2023.03.19.23287458
A1 Huang, Kexin
A1 Chandak, Payal
A1 Wang, Qianwen
A1 Havaldar, Shreyas
A1 Vaid, Akhil
A1 Leskovec, Jure
A1 Nadkarni, Girish
A1 Glicksberg, Benjamin S.
A1 Gehlenborg, Nils
A1 Zitnik, Marinka
YR 2024
UL http://medrxiv.org/content/early/2024/08/07/2023.03.19.23287458.abstract
AB Drug repurposing – identifying new therapeutic uses for approved drugs – is often serendipitous and opportunistic, expanding the use of drugs for new diseases. The clinical utility of drug repurposing AI models remains limited because the models focus narrowly on diseases for which some drugs already exist. Here, we introduce TxGNN, a graph foundation model for zero-shot drug repurposing, identifying therapeutic candidates even for diseases with limited treatment options or no existing drugs. Trained on a medical knowledge graph, TxGNN utilizes a graph neural network and metric-learning module to rank drugs as potential indications and contraindications across 17,080 diseases. When benchmarked against eight methods, TxGNN improves prediction accuracy for indications by 49.2% and contraindications by 35.1% under stringent zero-shot evaluation. To facilitate model interpretation, TxGNN’s Explainer module offers transparent insights into multi-hop medical knowledge paths that form TxGNN’s predictive rationales. Human evaluation of TxGNN’s Explainer showed that TxGNN’s predictions and explanations perform encouragingly on multiple axes of performance beyond accuracy. Many of TxGNN’s novel predictions align with off-label prescriptions clinicians make in a large healthcare system. TxGNN’s drug repurposing predictions are accurate, consistent with off-label drug use, and can be investigated by human experts through multi-hop interpretable rationales.Competing Interest StatementThe authors have declared no competing interest.Funding StatementK.H., P.C., and M.Z.~gratefully acknowledge the support of NIH R01-HD108794, US DoD FA8702-15-D-0001, awards from Harvard Data Science Initiative, Amazon Faculty Research, Google Research Scholar Program, Bayer Early Excellence in Science, AstraZeneca Research, Roche Alliance with Distinguished Scientists, and Kempner Institute for the Study of Natural and Artificial Intelligence at Harvard University. P.C. was supported, in part, by the Harvard Summer Institute in Biomedical Informatics. Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical and electronic medical record data were deidentified, and the Institutional Review Board at Mount Sinai, New York City, U.S., approved the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe TxGNN's project website is at https://zitniklab.hms.harvard.edu/projects/TxGNN. Therapeutics-centered knowledge graph is available at https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/IXA7BM under a persistent identifier https://doi.org/10.7910/DVN/IXA7BM. We have deposited the knowledge graph and all relevant intermediate files in this repository. Python implementation of the methodology developed and used in the study is available via the project website at https://zitniklab.hms.harvard.edu/projects/TxGNN. The code to reproduce results, documentation, and usage examples are at https://github.com/mims-harvard/TxGNN. To facilitate the usage of the algorithm, we developed a TxGNN Explorer, a web-based app available at http://txgnn.org to access TxGNN's predictions. https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/IXA7BM https://zitniklab.hms.harvard.edu/projects/TxGNN http://txgnn.org https://github.com/mims-harvard/TxGNN